|
1
|
Stanton SE, Adams S and Disis ML:
Variation in incidence and magnitude of tumor-infiltrating
lymphocytes in breast cancer subtypes: A systematic review. JAMA
Oncol. 2:1354–1360. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Klein E, Becker S, Svedmyr E, Jondal M and
Vánky F: Tumor infiltrating lymphocytes. Ann N Y Acad Sci.
276:207–216. 1976. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Galon J, Angell HK, Bedognetti D and
Marincola FM: The continuum of cancer immunosurveillance:
Prognostic, predictive, and mechanistic signatures. Immunity.
39:11–26. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Savas P, Salgado R, Denkert C, Sotiriou C,
Darcy PK, Smyth MJ and Loi S: Clinical relevance of host immunity
in breast cancer: From TILs to the clinic. Nat Rev Clin Oncol.
13:228–241. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Salgado R, Denkert C, Campbell C, Savas P,
Nuciforo P, Aura C, de Azambuja E, Eidtmann H, Ellis CE, Baselga J,
et al: Tumor-infiltrating lymphocytes and associations with
pathological complete response and event-free survival in
HER2-positive early-stage breast cancer treated with lapatinib and
trastuzumab: A secondary analysis of the NeoALTTO Trial. JAMA
Oncol. 1:448–454. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Denkert C, Loibl S, Noske A, Roller M,
Müller BM, Komor M, Budczies J, Darb-Esfahani S, Kronenwett R,
Hanusch C, et al: Tumor-associated lymphocytes as an independent
predictor of response to neoadjuvant chemotherapy in breast cancer.
J Clin Oncol. 28:105–113. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Issa-Nummer Y, Darb-Esfahani S, Loibl S,
Kunz G, Nekljudova V, Schrader I, Sinn BV, Ulmer HU, Kronenwett R,
Just M, et al: Prospective validation of immunological infiltrate
for prediction of response to neoadjuvant chemotherapy in
HER2-negative breast cancer-a substudy of the neoadjuvant
GeparQuinto trial. PLoS One. 8:e797752013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Denkert C, von Minckwitz G, Brase JC, Sinn
BV, Gade S, Kronenwett R, Pfitzner BM, Salat C, Loi S, Schmitt WD,
et al: Tumor-infiltrating lymphocytes and response to neoadjuvant
chemotherapy with or without carboplatin in human epidermal growth
factor receptor 2-positive and triple-negative primary breast
cancers. J Clin Oncol. 33:983–991. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
West NR, Milne K, Truong PT, Macpherson N,
Nelson BH and Watson PH: Tumor-infiltrating lymphocytes predict
response to anthracycline-based chemotherapy in estrogen
receptor-negative breast cancer. Breast Cancer Res. 13:R1262011.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Salgado R, Denkert C, Demaria S, Sirtaine
N, Klauschen F, Pruneri G, Wienert S, Van den Eynden G, Baehner FL,
Penault-Llorca F, et al: The evaluation of tumor-infiltrating
lymphocytes (TILs) in breast cancer: Recommendations by an
International TILs Working Group 2014. Ann Oncol. 26:259–271. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hammond ME, Hayes DF, Dowsett M, Allred
DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS,
Hayes M, et al: American Society of Clinical Oncology/College Of
American Pathologists guideline recommendations for
immunohistochemical testing of estrogen and progesterone receptors
in breast cancer. J Clin Oncol. 28:2784–2795. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wolff AC, Hammond ME, Hicks DG, Dowsett M,
McShane LM, Allison KH, Allred DC, Bartlett JM, Bilous M,
Fitzgibbons P, et al: Recommendations for human epidermal growth
factor receptor 2 testing in breast cancer: American Society of
Clinical Oncology/College of American Pathologists clinical
practice guideline update. Arch Pathol Lab Med. 138:241–256. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Loi S, Sirtaine N, Piette F, Salgado R,
Viale G, Van Eenoo F, Rouas G, Francis P, Crown JP, Hitre E, et al:
Prognostic and predictive value of tumor-infiltrating lymphocytes
in a phase III randomized adjuvant breast cancer trial in
node-positive breast cancer comparing the addition of docetaxel to
doxorubicin with doxorubicin-based chemotherapy: BIG 02–98. J Clin
Oncol. 31:860–867. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Adams S, Gray RJ, Demaria S, Goldstein L,
Perez EA, Shulman LN, Martino S, Wang M, Jones VE, Saphner TJ, et
al: Prognostic value of tumor-infiltrating lymphocytes in
triplenegative breast cancers from two phase III randomized
adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin
Oncol. 32:2959–2966. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Loi S, Drubay D, Adams S, Francis PA,
Joensuu H, Dieci MV, Badve S, Demaria S, Gray R, Piccart MJ, et al:
Pooled individual patient data analysis of stromal tumor
infiltrating lymphocytes in primary triple negative breast cancer
treated with anthracyclinebased chemotherapy. Cancer Res. 76
(suppl):abstr S1-03. 2016. View Article : Google Scholar
|
|
16
|
Loi S, Michiels S, Salgado R, Sirtaine N,
Jose V, Fumagalli D, Kellokumpu-Lehtinen PL, Bono P, Kataja V,
Desmedt C, et al: Tumor infiltrating lymphocytes are prognostic in
triple negative breast cancer and predictive for trastuzumab
benefit in early breast cancer: Results from the FinHER trial. Ann
Oncol. 25:1544–1550. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Denkert C, von Minckwitz G, Darb-Esfahani
S, Lederer B, Heppner BI, Weber KE, Budczies J, Huober J, Klauschen
F, Furlanetto J, et al: Tumour-infiltrating lymphocytes and
prognosis in different subtypes of breast cancer: A pooled analysis
of 3771 patients treated with neoadjuvant therapy. Lancet Oncol.
19:40–50. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Heindl A, Sestak I, Naidoo K, Cuzick J,
Dowsett M and Yuan Y: Relevance of Spatial Heterogeneity of Immune
Infiltration for Predicting Risk of Recurrence After Endocrine
Therapy of ER+ Breast Cancer. J Natl Cancer Inst.
110:2018. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kurozumi S, Fujii T, Matsumoto H, Inoue K,
Kurosumi M, Horiguchi J and Kuwano H: Significance of evaluating
tumor-infiltrating lymphocytes (TILs) and programmed cell
death-ligand 1 (PD-L1) expression in breast cancer. Med Mol
Morphol. 50:185–194. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Goodman AM, Kato S, Bazhenova L, Patel SP,
Frampton GM, Miller V, Stephens PJ, Daniels GA and Kurzrock R:
Tumor mutational burden as an independent predictor of response to
immunotherapy in diverse cancers. Mol Cancer Ther. 16:2598–2608.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Pereira B, Chin SF, Rueda OM, Vollan HK,
Provenzano E, Bardwell HA, Pugh M, Jones L, Russell R, Sammut SJ,
et al: The somatic mutation profiles of 2,433 breast cancers
refines their genomic and transcriptomic landscapes. Nat Commun.
7:114792016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Haricharan S, Bainbridge MN, Scheet P and
Brown PH: Somatic mutation load of estrogen receptor-positive
breast tumors predicts overall survival: An analysis of genome
sequence data. Breast Cancer Res Treat. 146:211–220. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Svoronos N, Perales-Puchalt A, Allegrezza
MJ, Rutkowski MR, Payne KK, Tesone AJ, Nguyen JM, Curiel TJ,
Cadungog MG, Singhal S, et al: Tumor cell-independent estrogen
signaling drives disease progression through mobilization of
myeloid-derived suppressor cells. Cancer Discov. 7:72–85. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Montagna E, Vingiani A, Maisonneuve P,
Cancello G, Contaldo F, Pruneri G and Colleoni M: Unfavorable
prognostic role of tumor-infiltrating lymphocytes in
hormone-receptor positive, HER2 negative metastatic breast cancer
treated with metronomic chemotherapy. Breast. 34:83–88. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Topalian SL, Taube JM, Anders RA and
Pardoll DM: Mechanism-driven biomarkers to guide immune checkpoint
blockade in cancer therapy. Nat Rev Cancer. 16:275–287. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Larkin J, Chiarion-Sileni V, Gonzalez R,
Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M,
Rutkowski P, et al: Combined nivolumab and ipilimumab or
monotherapy in untreated melanoma. N Engl J Med. 373:23–34. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Brahmer J, Reckamp KL, Baas P, Crinò L,
Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE,
Holgado E, et al: Nivolumab versus docetaxel in advanced
squamous-cell nonsmall-cell lung cancer. N Engl J Med. 373:123–135.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Motzer RJ, Rini BI, McDermott DF, Redman
BG, Kuzel TM, Harrison MR, Vaishampayan UN, Drabkin HA, George S,
Logan TF, et al: Nivolumab for metastatic renal cell carcinoma:
Results of a randomized phase II trial. J Clin Oncol. 33:1430–1437.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Nanda R, Chow LQ, Dees EC, Berger R, Gupta
S, Geva R, Pusztai L, Pathiraja K, Aktan G, Cheng JD, et al:
Pembrolizumab in patients with advanced triple-negative breast
cancer: Phase Ib KEYNOTE-012 study. J Clin Oncol. 34:2460–2467.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Gibney GT, Weiner LM and Atkins MB:
Predictive biomarkers for checkpoint inhibitor-based immunotherapy.
Lancet Oncol. 17:e542–e551. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zhang M, Sun H, Zhao S, Wang Y, Pu H, Wang
Y and Zhang Q: Expression of PD-L1 and prognosis in breast cancer:
A meta-analysis. Oncotarget. 8:31347–31354. 2017.PubMed/NCBI
|
|
32
|
Soliman H, Khalil F and Antonia S: PD-L1
expression is increased in a subset of basal type breast cancer
cells. PLoS One. 9:e885572014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Hendry S, Pang JB, Byrne DJ, Lakhani SR,
Cummings MC, Campbell IG, Mann GB, Gorringe KL and Fox SB:
Relationship of the breast ductal carcinoma in situ immune
microenvironment with clinicopathological and genetic features.
Clin Cancer Res. 23:5210–5217. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Tarhini AA, Zahoor H, Yearley JH, Gibson
C, Rahman Z, Dubner R, Rao UN, Sander C and Kirkwood JM: Tumor
associated PD-L1 expression pattern in microscopically tumor
positive sentinel lymph nodes in patients with melanoma. J Transl
Med. 13:3192015. View Article : Google Scholar : PubMed/NCBI
|
